![Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1α and induces DNA damage by sequestering ferrous iron | Cell Death & Disease Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1α and induces DNA damage by sequestering ferrous iron | Cell Death & Disease](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41419-018-1038-3/MediaObjects/41419_2018_1038_Fig8_HTML.png)
Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1α and induces DNA damage by sequestering ferrous iron | Cell Death & Disease
![Signal transduction mechanisms for lung cancer PAC1. Activated PAC1... | Download Scientific Diagram Signal transduction mechanisms for lung cancer PAC1. Activated PAC1... | Download Scientific Diagram](https://www.researchgate.net/publication/221887161/figure/fig3/AS:305282061225987@1449796323703/Signal-transduction-mechanisms-for-lung-cancer-PAC1-Activated-PAC1-interacts-with-G.png)
Signal transduction mechanisms for lung cancer PAC1. Activated PAC1... | Download Scientific Diagram
Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential | ACS Chemical Biology
![PACAP38 and PAC1 receptor blockade: a new target for headache? | The Journal of Headache and Pain | Full Text PACAP38 and PAC1 receptor blockade: a new target for headache? | The Journal of Headache and Pain | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs10194-018-0893-8/MediaObjects/10194_2018_893_Fig1_HTML.png)
PACAP38 and PAC1 receptor blockade: a new target for headache? | The Journal of Headache and Pain | Full Text
Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro | PLOS ONE
![Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies | British Journal of Cancer Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-022-02089-7/MediaObjects/41416_2022_2089_Fig1_HTML.png)
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies | British Journal of Cancer
![Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 - Full Text View - ClinicalTrials.gov Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 - Full Text View - ClinicalTrials.gov](https://www.clinicaltrials.gov/ct2/html/images/warning.png)
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 - Full Text View - ClinicalTrials.gov
![Frontiers | Platelet Protease Activated Receptor 1 Is Involved in the Hemostatic Effect of 20(S)-Protopanaxadiol by Regulating Calcium Signaling Frontiers | Platelet Protease Activated Receptor 1 Is Involved in the Hemostatic Effect of 20(S)-Protopanaxadiol by Regulating Calcium Signaling](https://www.frontiersin.org/files/Articles/549150/fphar-11-549150-HTML/image_m/fphar-11-549150-g005.jpg)